SCHEMBL7072159

SCHEMBL7072159

N=C(N)Nc1ccc(Cl)cc1C(=O)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.67
ALDH1A1 P00352 5/20 0.65
LMNA P02545 3/20 0.65
TP53 P04637 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
SERPINE1 P05121 1/20 0.59
GAA P10253 2/20 0.57
POLB P06746 2/20 0.55
MEN1 O00255 1/20 0.55
MAPK1 P28482 1/20 0.55
KMT2A Q03164 1/20 0.55
KDM4E B2RXH2 1/20 0.55
HTT P42858 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27611956 0.90 MAPT (0.72) MAPTALDH1A1LMNATP53SMN1; SMN2
SCHEMBL1306598 0.89 MAPT (0.61) MAPTALDH1A1LMNATP53SMN1; SMN2
SCHEMBL7072156 0.88 MAPT (0.70) MAPTALDH1A1LMNATP53SMN1; SMN2
SCHEMBL11571840 0.84 MAPT (0.86) MAPTALDH1A1LMNATP53SMN1; SMN2
SCHEMBL11827090 0.82 MAPT (0.72) MAPTALDH1A1LMNATP53SMN1; SMN2
SCHEMBL31000396 0.82 MAPT (0.72) MAPTALDH1A1LMNATP53SMN1; SMN2
SCHEMBL31358138 0.82 ALDH1A1 (0.59) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL11795244 0.82 ALDH1A1 (0.59) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL12112128 0.81 MAPT (0.61) MAPTALDH1A1LMNATP53SMN1; SMN2
SCHEMBL31384417 0.80 MAPT (0.67) MAPTALDH1A1LMNATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030219718-A1 Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same UNIVERSITY OF MARYLAND, BALTIMORE 2003-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030219718-A1 Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same TP53, S100P, S100A4 MAPT 1570/4885ALDH1A1 3844/4885LMNA 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.